Advertisement

Imaging in Localized and Advanced Bladder Cancer

  • Timothy Kim
  • Joshua G. Griffin
  • Jeffrey M. Holzbeierlein
  • Wade J. SextonEmail author
Chapter

Abstract

Bladder cancer is the most common neoplasm of the urinary tract and imaging has become vital in both the diagnosis and management of these patients. There are many different imaging modalities (e.g. ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography, bone scans), each with their specific applications. It is important to understand the merits of each modality to use them in the proper clinical setting. As the use of neoadjuvant chemotherapy becomes more prevalent, accurate clinical staging of patients with advanced disease is paramount. This chapter discusses the role of multiple imaging modalities in the setting of both non-muscle invasive and muscle invasive bladder cancer, as well as in the setting of neoadjuvant chemotherapy and surveillance.

Keywords

Urothelial carcinoma Bladder cancer Radiology Imaging Staging Computed tomography Positron emission tomography Magnetic resonance imaging 

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;2(1):10–29 [Comparative Study].CrossRefGoogle Scholar
  2. 2.
    Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ, et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol. 2012;188(6 Suppl):2473–81.PubMedCrossRefGoogle Scholar
  3. 3.
    Amling CL. Diagnosis and management of superficial bladder cancer. Curr Probl Cancer. 2001;25(4):219–78.PubMedCrossRefGoogle Scholar
  4. 4.
    Kundra V, Silverman PM. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. Am J Roentgenol. 2003;180(4):1045–54.CrossRefGoogle Scholar
  5. 5.
    Datta SN, Allen GM, Evans R, Vaughton KC, Lucas MG. Urinary tract ultrasonography in the evaluation of haematuria – a report of over 1,000 cases. Ann R Coll Surg Engl. 2002;84(3):203–5.PubMedCentralPubMedGoogle Scholar
  6. 6.
    Malone PR, Weston-Underwood J, Aron PM, Wilkinson KW, Joseph AE, Riddle PR. The use of transabdominal ultrasound in the detection of early bladder tumours. Br J Urol. 1986;58(5):520–2.PubMedCrossRefGoogle Scholar
  7. 7.
    Ozden E, Turgut AT, Turkolmez K, Resorlu B, Safak M. Effect of bladder carcinoma location on detection rates by ultrasonography and computed tomography. Urology. 2007;69(5):889–92.PubMedCrossRefGoogle Scholar
  8. 8.
    Abu-Yousef MM, Narayana AS, Franken Jr EA, Brown RC. Urinary bladder tumors studied by cystosonography. Part I: detection. Radiology. 1984;153(1):223–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Quaia E. Microbubble ultrasound contrast agents: an update. Eur Radiol. 2007;17(8):1995–2008.PubMedCrossRefGoogle Scholar
  10. 10.
    Caruso G, Salvaggio G, Campisi A, Melloni D, Midiri M, Bertolotto M, et al. Bladder tumor staging: comparison of contrast-enhanced and gray-scale ultrasound. Am J Roentgenol. 2010;194(1):151–6.CrossRefGoogle Scholar
  11. 11.
    Nicolau C, Bunesch L, Peri L, Salvador R, Corral JM, Mallofre C, et al. Accuracy of contrast-enhanced ultrasound in the detection of bladder cancer. Br J Radiol. 2011;84(1008):1091–9.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Li QY, Tang J, He EH, Li YM, Zhou Y, Zhang X, et al. Clinical utility of three-dimensional contrast-enhanced ultrasound in the differentiation between noninvasive and invasive neoplasms of urinary bladder. Eur J Radiol. 2012;81(11):2936–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Wang LJ, Wong YC, Ng KF, Chuang CK, Lee SY, Wan YL. Tumor characteristics of urothelial carcinoma on multidetector computerized tomography urography. J Urol. 2010;183(6):2154–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Turney BW, Willatt JM, Nixon D, Crew JP, Cowan NC. Computed tomography urography for diagnosing bladder cancer. BJU Int. 2006;98(2):345–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Blick CG, Nazir SA, Mallett S, Turney BW, Onwu NN, Roberts IS, et al. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int. 2012;110(1):84–94.PubMedCrossRefGoogle Scholar
  16. 16.
    Sadow CA, Silverman SG, O’Leary MP, Signorovitch JE. Bladder cancer detection with CT urography in an Academic Medical Center. Radiology. 2008;249(1):195–202.PubMedCrossRefGoogle Scholar
  17. 17.
    Rajesh A, Sokhi HK, Fung R, Mulcahy KA, Bankart MJ. Bladder cancer: evaluation of staging accuracy using dynamic MRI. Clin Radiol. 2011;66(12):1140–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Green DA, Rink M, Hansen J, Cha EK, Robinson B, Tian Z, et al. Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. BJU Int. 2013;111(3):404–11.PubMedCrossRefGoogle Scholar
  19. 19.
    Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Genitourinary Cancer Disease Site Group CCOPiE-bCPGI. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004;171(2 Pt 1):561–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Svatek RS, Shariat SF, Novara G, Skinner EC, Fradet Y, Bastian PJ, et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 2011;107(6):898–904.PubMedCrossRefGoogle Scholar
  21. 21.
    Stimson CJ, Cookson MS, Barocas DA, Clark PE, Humphrey JE, Patel SG, et al. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol. 2010;183(5):1732–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Matsuki M, Inada Y, Tatsugami F, Tanikake M, Narabayashi I, Katsuoka Y. Diffusion-weighted MR imaging for urinary bladder carcinoma: initial results. Eur Radiol. 2007;17(1):201–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Takeuchi M, Sasaki S, Ito M, Okada S, Takahashi S, Kawai T, et al. Urinary bladder cancer: diffusion-weighted MR imaging–accuracy for diagnosing T stage and estimating histologic grade. Radiology. 2009;251(1):112–21 [Evaluation Studies Research Support, Non-U.S. Gov’t].PubMedCrossRefGoogle Scholar
  24. 24.
    Watanabe H, Kanematsu M, Kondo H, Goshima S, Tsuge Y, Onozuka M, et al. Preoperative T staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value? Am J Roentgenol. 2009;192(5):1361–6.CrossRefGoogle Scholar
  25. 25.
    Jensen JB, Ulhoi BP, Jensen KM. Prognostic value of lymph-node dissection in patients undergoing radical cystectomy following previous oncological treatment for bladder cancer. Scand J Urol Nephrol. 2011;45(6):436–43.PubMedCrossRefGoogle Scholar
  26. 26.
    Yoshida S, Koga F, Kawakami S, Ishii C, Tanaka H, Numao N, et al. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. Urology. 2010;75(2):387–91.PubMedCrossRefGoogle Scholar
  27. 27.
    Mertens LS, Fioole-Bruining A, van Rhijn BW, Kerst JM, Bergman AM, Vogel WV, et al. FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer. J Urol. 2013;189(5):1687–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Dighe MK, Bhargava P, Wright J. Urinary bladder masses: techniques, imaging spectrum, and staging. J Comput Assist Tomogr. 2011;35(4):411–24 [Review].PubMedCrossRefGoogle Scholar
  29. 29.
    Ficarra V, Dalpiaz O, Alrabi N, Novara G, Galfano A, Artibani W. Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int. 2005;95(6):786–90.PubMedCrossRefGoogle Scholar
  30. 30.
    Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.PubMedCrossRefGoogle Scholar
  31. 31.
    Sherif A, Holmberg L, Rintala E, Mestad O, Nilsson J, Nilsson S, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol. 2004;45(3):297–303 [Research Support, Non-U.S. Gov’t].PubMedCrossRefGoogle Scholar
  32. 32.
    Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: nordic cystectomy trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol. 1996;155(6):1903–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Husband JE. Computer tomography and magnetic resonance imaging in the evaluation of bladder cancer. J Belge Radiol. 1995;78(6):350–5 [Research Support, Non-U.S. Gov’t Review].PubMedGoogle Scholar
  34. 34.
    Beyersdorff D, Zhang J, Schoder H, Bochner B, Hricak H. Bladder cancer: can imaging change patient management? Curr Opin Urol. 2008;18(1):98–104 [Review].PubMedCrossRefGoogle Scholar
  35. 35.
    Cowan NC, Crew JP. Imaging bladder cancer. Curr Opin Urol. 2010;20(5):409–13 [Review].PubMedCrossRefGoogle Scholar
  36. 36.
    Setty BN, Holalkere NS, Sahani DV, Uppot RN, Harisinghani M, Blake MA. State-of-the-art cross-sectional imaging in bladder cancer. Curr Probl Diagn Radiol. 2007;36(2):83–96 [Review].PubMedCrossRefGoogle Scholar
  37. 37.
    Voges GE, Tauschke E, Stockle M, Alken P, Hohenfellner R. Computerized tomography: an unreliable method for accurate staging of bladder tumors in patients who are candidates for radical cystectomy. J Urol. 1989;142(4):972–4 [Comparative Study].PubMedGoogle Scholar
  38. 38.
    Bryan PJ, Butler HE, LiPuma JP, Resnick MI, Kursh ED. CT and MR imaging in staging bladder neoplasms. J Comput Assist Tomogr. 1987;11(1):96–101 [Comparative Study].PubMedCrossRefGoogle Scholar
  39. 39.
    Yaman O, Baltaci S, Arikan N, Yilmaz E, Gogus O. Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour: comparison with final pathological stage in invasive bladder carcinoma. Br J Urol. 1996;78(2):197–200 [Comparative Study].PubMedCrossRefGoogle Scholar
  40. 40.
    Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol. 2000;163(6):1693–6 [Research Support, Non-U.S. Gov’t].PubMedCrossRefGoogle Scholar
  41. 41.
    Baltaci S, Resorlu B, Yagci C, Turkolmez K, Gogus C, Beduk Y. Computerized tomography for detecting perivesical infiltration and lymph node metastasis in invasive bladder carcinoma. Urol Int. 2008;81(4):399–402.PubMedCrossRefGoogle Scholar
  42. 42.
    Tilki D, Brausi M, Colombo R, Evans CP, Fradet Y, Fritsche HM, et al. Lymphadenectomy for bladder cancer at the time of radical cystectomy. Eur Urol. 2013;64(2):266–76.PubMedCrossRefGoogle Scholar
  43. 43.
    Verma S, Rajesh A, Prasad SR, Gaitonde K, Lall CG, Mouraviev V, et al. Urinary bladder cancer: role of MR imaging. Radiographics. 2012;32(2):371–87 [Research Support, Non-U.S. Gov’t Review].PubMedCrossRefGoogle Scholar
  44. 44.
    Tekes A, Kamel I, Imam K, Szarf G, Schoenberg M, Nasir K, et al. Dynamic MRI of bladder cancer: evaluation of staging accuracy. Am J Roentgenol. 2005;184(1):121–7.CrossRefGoogle Scholar
  45. 45.
    Vargas HA, Akin O, Schoder H, Olgac S, Dalbagni G, Hricak H, et al. Prospective evaluation of MRI, (1)(1)C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. Eur J Radiol. 2012;81(12):4131–7 [Comparative Study].PubMedCrossRefGoogle Scholar
  46. 46.
    Braendengen M, Winderen M, Fossa SD. Clinical significance of routine pre-cystectomy bone scans in patients with muscle-invasive bladder cancer. Br J Urol. 1996;77(1):36–40.PubMedCrossRefGoogle Scholar
  47. 47.
    Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging. 2005;32(12):1412–7 [Clinical Trial].PubMedCrossRefGoogle Scholar
  48. 48.
    Bachor R, Kotzerke J, Reske SN, Hautmann R. Lymph node staging of bladder neck carcinoma with positron emission tomography. Urologe A. 1999;38(1):46–50.PubMedCrossRefGoogle Scholar
  49. 49.
    Kibel AS, Dehdashti F, Katz MD, Klim AP, Grubb RL, Humphrey PA, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol. 2009;27(26):4314–20.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34(4):274–92 [Review].PubMedCrossRefGoogle Scholar
  51. 51.
    Network NCC. Bladder cancer. Fort Washington, PA, Version I. 2013 [cited 2013 September 1]; Available from: www.nccn.org

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Timothy Kim
    • 1
  • Joshua G. Griffin
    • 2
  • Jeffrey M. Holzbeierlein
    • 3
  • Wade J. Sexton
    • 1
    Email author
  1. 1.Department of Genitourinary OncologyMoffitt Cancer CenterTampaUSA
  2. 2.Department of UrologyUniversity of Kansas Medical CenterKansas CityUSA
  3. 3.University of Kansas HospitalKansas CityUSA

Personalised recommendations